EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Myovant Sciences's enterprise value is $2,716.5 Mil.
Myovant Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-140.4 Mil. Therefore, Myovant Sciences's EV-to-EBITDA for today is -19.34.
The historical rank and industry rank for Myovant Sciences's EV-to-EBITDA or its related term are showing as below:
MYOV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.34 Med: -7.34 Max: -4.09
Current: -19.34
During the past 7 years, the highest EV-to-EBITDA of Myovant Sciences was -4.09. The lowest was -19.34. And the median was -7.34.
MYOV's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.34
vs MYOV: -19.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Myovant Sciences EV-to-EBITDA Historical Data
The historical data trend for Myovant Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myovant Sciences's EV-to-EBITDA
For the Biotechnology subindustry, Myovant Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Myovant Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's EV-to-EBITDA falls into.
Myovant Sciences's current Enterprise Value is $2,716.5 Mil.
Myovant Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-140.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Myovant Sciences's PE Ratio for today is calculated as:
Myovant Sciences's share price for today is $26.98.
Myovant Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Myovant Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences (Myovant Sciences) Business Description
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYOV has been successfully added to your 